Takeaways: SteriMax’s acquisition of Andone broadens its growth runway beyond injectables into two adjacent, higher-diversification markets, medical devices and veterinary, so the main mark...
Takeaways: Vimkunya’s Health Canada approval turns Bavarian Nordic’s chikungunya shot into a genuinely global travel-vaccine franchise, which should drive uptake in Canadian travel cl...
For most of modern medicine, the pharmaceutical industry has operated largely within a reactive healthcare model, developing therapies designed to treat diseases after they emerge. Today, however, adv...
Takeaways: Boey gives Allergan Aesthetics a differentiated entry point in Canadian aesthetics: a fast-onset, short-duration botulinum option that can attract first-time or co...
Artificial intelligence is rapidly becoming embedded across the pharmaceutical value chain, from drug discovery and clinical trial optimization to manufacturing and commercialization. As the technolog...
Takeaways: Roche’s pCPA win for Itovebi is a major reimbursement de-risking event in Canada, because it moves the drug much closer to broad public coverage after a ...
Takeaways: Zasocitinib’s Phase 3 win over deucravacitinib suggests it could become a best-in-class oral TYK2 option for moderate-to-severe plaque psoriasis if regulators...
Takeaways: The new products expand Organon’s Canadian biosimilars line to eight drugs across five therapeutic areas, including oncology, strengthening its position as a major biosimilar sup...
Takeaways: Expanded Canadian partnership positions Organon as the exclusive commercialization partner for Samsung Bioepis’s ustekinumab biosimilar Pyzchiva (Stelara reference), creating a six-pr...
Takeaways: This approval strengthens Lilly’s competitive stance against other GLP-1/GIP agents in the obesity space by adding a disease-specific indication (OSA) that ties directl...